<DOC>
	<DOCNO>NCT02859129</DOCNO>
	<brief_summary>This study intend evaluate potential 2-way reciprocal interaction multiple dose Epanova™ single dose rosuvastatin</brief_summary>
	<brief_title>Study Evaluate 2-Way Interaction Between Multiple Doses Epanova™ Single Dose Rosuvastatin ( Crestor® )</brief_title>
	<detailed_description>The PK rosuvastatin monitor follow single-dose administration rosuvastatin without multiple-dose administration 4 g Epanova™ 13 consecutive day order detect possible interaction rosuvastatin Epanova™ . The PK total EPA , total DHA total EPA+DHA also monitor follow multiple-dose administration Epanova™ without single-dose administration 40 mg rosuvastatin . A single dose administration rosuvastatin judge sufficient yield plasma concentration detectable adequate validate analytical method characterize adequately PK rosuvastatin .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Male female ( nonchildbearing potential ) Body Mass Index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 screen Nonsmoker Medically healthy clinically significant laboratory profile , vital sign ECGs mentally legally incapacitated significant emotional problem time screen visit expect conduct study History presence myopathy and/or hypothyroidism . History presence transaminase elevation History presence hypersensitivity idiosyncratic reaction rosuvastatin , HMGCoA reductase inhibitor , Epanova™ , Vascepa® , related compound Known sensitivity allergy soybean , fish , and/or shellfish . Has consume fish within 7 day prior checkin . Female subject pregnant lactating . Positive urine drug alcohol result screen checkin . Positive urine cotinine screen checkin Use drug know inducer CYP enzymes and/or Pgp Donation blood significant blood loss within 56 day prior first dose study medication . Plasma donation within 7 day prior first dose study medication . Participation another clinical trial within 28 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Epanova</keyword>
	<keyword>omega-3 carboxylic acid</keyword>
	<keyword>Vascepa</keyword>
	<keyword>Eicosapentaenoic acid ethyl ester</keyword>
	<keyword>Crestor</keyword>
	<keyword>rosuvastatin</keyword>
</DOC>